- Home
- SFST vs ZNTL Comparison
SFST vs ZNTL Comparison
Compare SFST & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SFST | ZNTL |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.7M | 468.9M |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SFST | ZNTL |
|---|---|---|
| Price | $56.97 | $4.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $64.00 | $6.60 |
| AVG Volume (30 Days) | 153.1K | ★ 4.4M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.76 | 18.03 |
| EPS | ★ 3.72 | N/A |
| Revenue | ★ $6,282,000.00 | N/A |
| Revenue This Year | $10.47 | N/A |
| Revenue Next Year | $12.19 | N/A |
| P/E Ratio | $15.16 | ★ N/A |
| Revenue Growth | ★ 12.99 | N/A |
| 52 Week Low | $34.51 | $1.13 |
| 52 Week High | $62.00 | $6.95 |
Technical Indicators
Market Signals| Indicator | SFST | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 53.81 | 53.52 |
| Support Level | $50.92 | $3.75 |
| Resistance Level | $58.40 | $6.95 |
| Average True Range (ATR) | 2.11 | 0.45 |
| MACD | -0.11 | -0.11 |
| Stochastic Oscillator | 58.47 | 15.24 |
Price Performance
Historical ComparisonAbout SFST Southern First Bancshares Inc.
Southern First Bancshares Inc is a bank holding company. Through its banking subsidiary, it is engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer, and mortgage loans, ATM processing, and other banking products and services to the general public. The group operates through various retail offices located in the Greenville, Columbia, and Charleston markets of South Carolina, three retail offices in the Raleigh, Greensboro, and Charlotte markets of North Carolina, and one retail office in Atlanta, Georgia.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.